Template:Prenatal Diagnosis terms: Difference between revisions

From Embryology
mNo edit summary
mNo edit summary
 
(14 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Prenatal Diagnosis Terms==
 
[[Prenatal Diagnosis|'''Prenatal Diagnosis Terms''']]
* '''ART''' - [[Assisted Reproductive Technology]] a general term to describe all the clinical techniques used to aid fertility.
 
* '''blastomere biopsy''' -  An ART preimplantation genetic diagnosis technique carried out at cleavage stage (day 3), excluding poor quality embryos, detects chromosomal abnormalities of both maternal and paternal origin. May not detect cellular mosaicism in the embryo.
 
* '''blastocyst biopsy''' - An ART preimplantation genetic diagnosis technique carried out at blastocyst stage (day 4-5), removes several trophoblast (trophoderm) cells, detects chromosomal abnormalities of both maternal and paternal origin and may detect cellular mosaicism.
 
* '''cell-free fetal deoxyribonucleic acid''' - (cfDNA) refers to fetal DNA circulating and isolated from the plasma portion of maternal blood.  Can be performed from {{GA}} 10 weeks as a first-tier test or as a second-tier test, with women with increased probability on combined first trimester screening offered cfDNA or diagnostic testing.


* '''false negative rate''' - The proportion of pregnancies that will test negative given that the congenital anomaly is present.
* '''false negative rate''' - The proportion of pregnancies that will test negative given that the congenital anomaly is present.
* '''false positive rate''' - The proportion of pregnancies that will test positive given that the congenital anomaly is absent.
* '''false positive rate''' - The proportion of pregnancies that will test positive given that the congenital anomaly is absent.
* '''free β human chorionic gonadotrophin''' - beta-{{hCG}} subunit of {{hCG}} used as a diagnostic marker for: early detection of pregnancy, {{trisomy 21}}, spontaneous abortion, ectopic pregnancy, {{hydatidiform mole}} or choriocarcinoma.
* '''multiples of the median''' - (MoM) A multiple of the median is a measure of how far an individual test result deviates from the median and is used to report the results of medical screening tests, particularly where the results of the individual tests are highly variable.
* '''negative predictive value''' - The probability that a congenital anomaly is absent given that the prenatal screening test is negative.
* '''negative predictive value''' - The probability that a congenital anomaly is absent given that the prenatal screening test is negative.
* [[Non-Invasive Prenatal Testing|'''Non-Invasive Prenatal Testing''']] - (NIPT) could refer to ultrasound or other imaging techniques, but more frequently used to describe analysis of cell-free fetal DNA circulating in maternal blood.
* '''polar body biopsy''' - (PB biopsy) An ART preimplantation genetic diagnosis technique that removes either the first or second polar body from the zygote. As these are generated by oocyte meiosis they detects chromosomal abnormalities only on the female genetics.
* '''positive predictive value''' - The probability that a congenital anomaly is present given that the prenatal screening test is positive.
* '''positive predictive value''' - The probability that a congenital anomaly is present given that the prenatal screening test is positive.
* '''pre-implantation genetic diagnosis''' - (PGD) a screening procedure for embryos produced through in vitro fertilisation (IVF) for genetic diseases that would generate developmental abnormalities or serious postnatal diseases.
 
* [[Preimplantation Genetic Diagnosis|'''pre-implantation genetic diagnosis''']] - (PGD, pre-implantation genetic screening) a diagnostic procedure for embryos produced through [[Assisted Reproductive Technology]] (ART, in vitro fertilisation, IVF) for genetic diseases that would generate developmental abnormalities or serious postnatal diseases.
 
* '''prenatal screening sensitivity''' - (detection rate) The probability of testing positive on a prenatal screening test if the congenital anomaly is present.
* '''prenatal screening sensitivity''' - (detection rate) The probability of testing positive on a prenatal screening test if the congenital anomaly is present.
* '''prenatal screening specificity''' - The probability of testing negative on a prenatal screening test if the congenital anomaly is absent.
* '''prenatal screening specificity''' - The probability of testing negative on a prenatal screening test if the congenital anomaly is absent.
<noinclude>[[Category:Template]]</noinclude>
 
* '''quadruple test''' (maternal serum testing of a-fetoprotein {{AFP}}, free B-hCG or total hCG, unconjugated estriol, and inhibin A)  is a fetal chromosomal anomaly test usually carried out later in pregnancy ({{GA}} 14 to 20 weeks).
 
* '''single nucleotide polymorphisms''' - (SNPs) the variation in a single DNA nucleotide that occurs at a specific position in the genome.
 
* '''triple test''' - (maternal serum testing of a-fetoprotein {{AFP}}, free B-hCG or total hCG, and unconjugated estriol) is a fetal chromosomal anomaly test usually carried out later in pregnancy ({{GA}} 14 to 20 weeks).
 
 
{{Terms lists}}<noinclude>[[Category:Template]]</noinclude>

Latest revision as of 12:43, 17 February 2020

Prenatal Diagnosis Terms

  • blastomere biopsy - An ART preimplantation genetic diagnosis technique carried out at cleavage stage (day 3), excluding poor quality embryos, detects chromosomal abnormalities of both maternal and paternal origin. May not detect cellular mosaicism in the embryo.
  • blastocyst biopsy - An ART preimplantation genetic diagnosis technique carried out at blastocyst stage (day 4-5), removes several trophoblast (trophoderm) cells, detects chromosomal abnormalities of both maternal and paternal origin and may detect cellular mosaicism.
  • cell-free fetal deoxyribonucleic acid - (cfDNA) refers to fetal DNA circulating and isolated from the plasma portion of maternal blood. Can be performed from GA 10 weeks as a first-tier test or as a second-tier test, with women with increased probability on combined first trimester screening offered cfDNA or diagnostic testing.
  • false negative rate - The proportion of pregnancies that will test negative given that the congenital anomaly is present.
  • false positive rate - The proportion of pregnancies that will test positive given that the congenital anomaly is absent.
  • free β human chorionic gonadotrophin - beta-hCG subunit of hCG used as a diagnostic marker for: early detection of pregnancy, Trisomy 21, spontaneous abortion, ectopic pregnancy, hydatidiform mole or choriocarcinoma.
  • multiples of the median - (MoM) A multiple of the median is a measure of how far an individual test result deviates from the median and is used to report the results of medical screening tests, particularly where the results of the individual tests are highly variable.
  • negative predictive value - The probability that a congenital anomaly is absent given that the prenatal screening test is negative.
  • Non-Invasive Prenatal Testing - (NIPT) could refer to ultrasound or other imaging techniques, but more frequently used to describe analysis of cell-free fetal DNA circulating in maternal blood.
  • polar body biopsy - (PB biopsy) An ART preimplantation genetic diagnosis technique that removes either the first or second polar body from the zygote. As these are generated by oocyte meiosis they detects chromosomal abnormalities only on the female genetics.
  • positive predictive value - The probability that a congenital anomaly is present given that the prenatal screening test is positive.
  • prenatal screening sensitivity - (detection rate) The probability of testing positive on a prenatal screening test if the congenital anomaly is present.
  • prenatal screening specificity - The probability of testing negative on a prenatal screening test if the congenital anomaly is absent.
  • quadruple test (maternal serum testing of a-fetoprotein Template:AFP, free B-hCG or total hCG, unconjugated estriol, and inhibin A) is a fetal chromosomal anomaly test usually carried out later in pregnancy (GA 14 to 20 weeks).
  • single nucleotide polymorphisms - (SNPs) the variation in a single DNA nucleotide that occurs at a specific position in the genome.
  • triple test - (maternal serum testing of a-fetoprotein Template:AFP, free B-hCG or total hCG, and unconjugated estriol) is a fetal chromosomal anomaly test usually carried out later in pregnancy (GA 14 to 20 weeks).


Other Terms Lists  
Terms Lists: ART | Birth | Bone | Cardiovascular | Cell Division | Endocrine | Gastrointestinal | Genital | Genetic | Head | Hearing | Heart | Immune | Integumentary | Neonatal | Neural | Oocyte | Palate | Placenta | Radiation | Renal | Respiratory | Spermatozoa | Statistics | Tooth | Ultrasound | Vision | Historic | Drugs | Glossary